Patients able to achieve stringent complete response after undergoing autologous stem-cell transplantation for multiple myeloma achieved improved long-term outcomes, including overall survival and time to progression, compared with patients who achieved lesser levels of response.
The novel experimental drug sotatercept increased bone mineral density and bone formation in patients with osteolytic lesions of multiple myeloma who had not used bisphosphonates, a phase II study showed.
The combination of bortezomib, lenalidomide, and dexamethasone resulted in a partial response or better in more than 60% of patients with relapsed or refractory multiple myeloma, according to results of a phase II trial.
Results of a large meta-analysis indicated that treatment with lenalidomide for newly diagnosed multiple myeloma was associated with an increased risk for developing secondary hematologic malignancies.
Results from a phase I/II trial indicate that carfilzomib may be a safe and effective substitute for bortezomib in multiple myeloma patients whose disease progressed during treatment with a bortezomib-containing regimen.
More than one-third of African American patients with monoclonal gammopathy of undetermined significance or multiple myeloma were found to have an inherited risk factor for the disease, according to the results of a European study.
The International Myeloma Working Group recently released a consensus statement updating recommendations for the management and treatment of patients with multiple myeloma who are not eligible for standard autologous stem-cell transplantation.
In this interview we discuss the current management and latest treatments and agents in development for multiple myeloma with Dr. Kenneth Anderson of the Dana-Farber Cancer Institute.
Today we speak with Steven T. Rosen, MD, about a couple of the projects he and his group are working on, repurposing old drugs for the treatment of multiple myeloma, that will be presented this year at ASH.
